90befe3158
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Pentagon-Agent: Vida <HEADLESS>
51 lines
3.5 KiB
Markdown
51 lines
3.5 KiB
Markdown
---
|
|
type: source
|
|
title: "Pharmacovigilance Study of GLP-1 Receptor Agonists for Metabolic and Nutritional Adverse Events"
|
|
author: "Frontiers in Pharmacology"
|
|
url: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1416985/full
|
|
date: 2024-01-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: paper
|
|
status: unprocessed
|
|
priority: low
|
|
tags: [glp1, pharmacovigilance, metabolic, nutritional, faers, adverse-events, dehydration]
|
|
intake_tier: research-task
|
|
---
|
|
|
|
## Content
|
|
|
|
Pharmacovigilance analysis of GLP-1 receptor agonists for metabolic and nutritional adverse events across seven agents using FAERS data.
|
|
|
|
Key signal counts:
|
|
- Semaglutide: 20 signals; Dulaglutide: 22 signals; Liraglutide: 16 signals; Exenatide: 12; Tirzepatide: 11; Lixisenatide: 2; Albiglutide: 1
|
|
|
|
ROR values for metabolism/nutrition disorders:
|
|
- Semaglutide: ROR 3.34; Liraglutide: ROR 2.78; Exenatide: ROR 2.15
|
|
|
|
Dehydration as most serious metabolic adverse event:
|
|
- Semaglutide: 370 cases (25.10% of serious reports)
|
|
- Dulaglutide: 434 cases (20.90%)
|
|
- Liraglutide: 318 cases (23.93%)
|
|
- Tirzepatide: 70 cases (32.86%)
|
|
|
|
Authors' conclusion: "GLP-1 RAs have considerable potential for the treatment of eating disorders" despite safety concerns, given appetite-suppressing mechanisms.
|
|
|
|
## Agent Notes
|
|
**Why this matters:** Dehydration emerging as the dominant serious metabolic adverse event is relevant to the eating disorder risk story — dehydration + electrolyte disruption is one of the primary medical complications of both bulimia nervosa (purging) and anorexia nervosa (restricted intake). If GLP-1 GI side effects (nausea, vomiting, diarrhea) induce dehydration, and this is happening in patients with undetected purging behaviors, the harm pathway is amplified.
|
|
|
|
**What surprised me:** The authors' conclusion that GLP-1s "have considerable potential for the treatment of eating disorders" despite documenting significant adverse events — this optimistic framing in the face of pharmacovigilance signals is itself a data point about the field's willingness to interpret ambiguous evidence favorably.
|
|
|
|
**What I expected but didn't find:** Any eating disorder-specific adverse event breakdown in a metabolic/nutritional focus paper. The eating disorder signal is covered in the psychiatric pharmacovigilance literature, not here.
|
|
|
|
**KB connections:**
|
|
- [[continuous health monitoring is converging on a multi-layer sensor stack]] — dehydration is one of the first physiological changes that continuous monitoring (CGMs, electrolyte patches) could detect in GLP-1 users at ED risk
|
|
|
|
**Extraction hints:** Lower priority than other ED sources — useful for the dehydration-ED risk interaction but not primary evidence for the eating disorder signal itself. Recommend citing alongside NEDA/ANAD guidance on hydration monitoring.
|
|
|
|
**Context:** FAERS pharmacovigilance, lower precision than VigiBase multinational study. Primarily useful for context on the metabolic adverse event profile, not the psychiatric/eating disorder signal.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
|
|
WHY ARCHIVED: The dehydration finding creates a connection between GLP-1 adverse events and the continuous monitoring space — dehydration + electrolyte monitoring as a GLP-1 safety use case
|
|
EXTRACTION HINT: Secondary source for context; cite primarily for dehydration prevalence data, not eating disorder risk specifically.
|